BOROLTD Borosil Q3 FY25 results (Oct–Dec 2024) and concall
Borosil Limited delivered a robust performance for Q3 and 9M FY25, showcasing strong revenue growth across all key segments. Despite challenges from new pharmaceutical marketing practices impacting B2B sales and higher e-commerce customer acquisition costs, the company maintained healthy operating EBITDA margins. Management expressed confidence in long-term growth potential, driven by domestic manufacturing expansion, new product launches, and a strategic focus on premium and healthy product categories.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 274 | 338 |
| EBITDA | 41 | 54 |
| Net profit | 18 | 35 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
